A pill that could outsmart food allergies? trial tests remibrutinib

NCT ID NCT07768371

NEW Not yet recruiting Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This Phase 3 study is testing whether an oral drug called remibrutinib can help people with IgE-mediated allergies to peanuts, cow's milk, or hen's egg tolerate larger amounts of the allergen without symptoms. Adults and adolescents aged 12 to 65 will receive either the drug or a placebo for up to 52 weeks. The main goal is to see if more participants can eat a predefined amount of the allergen during a food challenge without a reaction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remibrutinib (LOU064), an oral drug
What this could lead to: If successful, this could lead to a daily pill that raises the amount of peanut, milk, or egg a person can eat without an allergic reaction, potentially reducing the risk from accidental exposure.
What could go wrong: The trial is still in progress, and results may not confirm benefit. The drug may cause side effects, and the effect could vary by allergen or person.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COW MILK ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Egg Hypersensitivity food allergy Heiner syndrome Milk Hypersensitivity Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COW MILK ALLERGY EGG ALLERGY IGE-MEDIATED FOOD ALLERGY PEANUT ALLERGY

More trials for these conditions

Other studies related to the condition(s) this trial covers.